Hansoh Pharma and GSK Announce Exclusive Global License Agreement for B7-H4 ADC HS-20089

Shanghai and LondonOctober 23, 2023PR Newswire -- Hansoh Pharma (03692.HK) and GSK (LSE/NYSE: GSK) jointly announced that they have entered into an exclusive licensing agreement for the ADC drug HS-20089. According to the agreement, Hansoh Pharma will grant GSK exclusive global rights (excluding mainland China, Hong Kong, Macao, and Taiwan) to develop and commercialize HS-20089.

HS-20089 is a novel B7-H4-targeting antibody-drug conjugate (ADC) currently undergoing Phase I clinical trials in China for the treatment of gynecological cancers. In addition to targeting the B7-H4 surface antigen, which is overexpressed in ovarian and endometrial cancers and is often associated with poor prognosis, HS-20089 also utilizes clinically validated ADC technology, specifically a topoisomerase inhibitor (TOPOi) payload. TOPOi represents a proven mechanism of action in approved anticancer drugs and is an established standard for treating breast and ovarian cancers.

Under the terms of the agreement, Hansoh Pharma will receive an upfront payment of $85 million and is eligible to receive up to $1.485 billion in success-based milestone payments. Following the product's commercialization, GSK will also pay tiered royalties on global net sales outside of mainland China, Hong Kong, Macao, and Taiwan. GSK plans to initiate Phase I clinical trials for HS-20089 outside of China in 2024.

Ms. Sun Yuan, Executive Director of Hansoh Pharma, stated: "We are very pleased to partner with GSK to further develop HS-20089. GSK's R&D expertise and commercial footprint in developing therapies for gynecological cancers make them an ideal partner to bring HS-20089 to patients outside of China."

As a leading innovation-driven pharmaceutical company in China, Hansoh Pharma is committed to meeting unmet clinical needs. Through independent research and development as well as BD collaboration, the company efficiently advances first-in-class (FIC) or best-in-class (BIC) global high-potential R&D pipelines, focusing on original and breakthrough innovations. Currently, over 30 innovative drug projects are undergoing more than 40 clinical trials, showcasing robust innovation momentum. The company will continue to deepen its innovation-driven strategy, bringing high-quality, accessible, and affordable treatment options to more patients in China and around the world.

About Hansoh Pharma

Hansoh Pharma is a leading innovation-driven pharmaceutical company in China, with subsidiaries including Hansoh Pharma, Changzhou Hengbang Pharma, and Hansoh Biomedicine. The company focuses on major disease treatment areas such as oncology, anti-infectives, central nervous system, metabolism, and autoimmune diseases, and is committed to improving the quality of human life through continuous innovation. To date, the company has launched seven innovative drugs, and the revenue share of innovative drugs has increased to 61.8%. The company has consistently ranked among the top 100 global pharmaceutical enterprises for many years and has been among the top three in China's best industrial enterprises for pharmaceutical R&D. It is a key national high-tech enterprise and a national technology innovation demonstration enterprise. The company was listed on the Hong Kong Stock Exchange in June 2019 (stock code: 03692.HK). For more information, please visit:https://cn.hspharm.com/。

About GSK

GSK is a global biopharmaceutical company with the mission to unite science, technology, and talent to defeat diseases. GSK is committed to maximizing patient survival through transformative medicines, currently focusing on breakthroughs in immuno-oncology and tumor cell-targeted therapies, as well as the development of hematologic malignancies, gynecologic cancers, and other solid tumors. For more information, please visit gsk.com.

Forward-Looking Statement

This article aims to provide relevant information about Hansoh Pharma or its subsidiaries and other related parties (collectively referred to as the "Company"), and does not constitute Company information disclosure or investment recommendation.

The information published in this article may contain certain forward-looking statements, such as those related to the prospects of the business and products, or the company’s plans, awareness, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. Due to their nature, they are all subject to relevant risks and uncertainties, some of which are beyond the company's control and difficult to predict. Investors should exercise caution when making investment decisions based on these statements. Any statements made using terms such as "committed to," "expect," "believe," "forecast," "anticipate," and other similar expressions, when related to the company, are considered forward-looking statements. The company has no obligation to update or revise these forward-looking statements, and neither the company, its directors, employees, nor agents shall bear any responsibility for any consequences arising from the failure or inaccuracy of any forward-looking statement.

All information in this press release is current as of the date of its release. Unless required by law, the company has no responsibility or obligation to update or modify such information, whether due to new data, future events, or other circumstances. Investors are advised to refer to Hansoh Pharma (03692.HK) announcements and financial reports for information solely related to the listed company.